Danish pharma giant Novo Nordisk has launched the world's fastest acting insulin for the patients living with diabetes in Bangladesh.
This insulin (fast-acting insulin aspart) will work four times faster than short acting human insulin, while two times faster than conventional rapid acting insulin. It can be used in people with type 1 and type 2 diabetes.
The announcement came at a press meet on the launching ceremony of the world's fastest acting insulin at a hotel in the capital today.
This new insulin can be used during pregnancy and breast-feeding period, the company said in a statement.
"People living with diabetes often struggle to control blood glucose especially around mealtimes. This can be extremely challenging and may result in devastating diabetes-related complications," said Professor Dr AK Azad Khan, president of Diabetic Association of Bangladesh (BADAS).
"I am really pleased to see that Novo Nordisk is playing a vital role in introducing research and development based innovative insulin for helping millions of diabetic patients in the country," said HE Winnie Estrup Petersen, ambassador of The Royal Embassy of Denmark in Bangladesh.
"As part of the Diabetic Association of Bangladesh's awareness and prevention programme, Novo Nordisk is closely working with us in creating nationwide awareness and education beside introducing innovative insulin," said Md Sayef Uddin, Secretary General, the Diabetic Association of Bangladesh.
"As a global leader in diabetes care, we are committed to introduce innovation for the benefit of people living with diabetes in Bangladesh," said Dr Mihail Briciu, managing director of Novo Nordisk Bangladesh.
Novo Nordisk in partnership with Eskayef Pharmaceuticals Ltd, a leading pharmaceutical company owned by Transcom Group, has been manufacturing insulin in Bangladesh since 2012. Transcom Distribution Company distributes the insulin across the country.
Dr Mohammad Mahbubur Rahman, head of Medical and Quality of Novo Nordisk; Md Tanbir Sajib, head of Commercial Affairs of Novo Nordisk; Gazi Towhid Ahmed, Public Affairs Manager of Novo Nordisk; and Mezba Ul Gaffar, Group Product Manager of Novo Nordisk were also present at the programme.